News

Tel Aviv, Israel -- Alpha Tau Medical – the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, and Medison Canada – a fully owned subsidiary of Medison Pharma, are pleased to announce that they have entered into an exclusive distribution arrangement.

M...

February 24, 2020

On November 28, 2019, the first Alpha DaRT procedure was performed in Russia, at the A. Tsyb Medical Radiological Research Center in Obninsk, in a patient diagnosed with metastatic breast cancer. Radiation Oncologist Dr. Razvan Galalae from Essen, Germany, performed th...

February 16, 2020

In August 2018, Jonathan and Na’ama Ellman, an Israeli couple living in the United States, brought their two-year-old son Ari to the emergency room for uncontrolled vomiting. Their whole world seemed to shatter when the doctors realized that the problem was caused by a...

February 11, 2020

As the new Chief Medical Officer of Alpha Tau Medical, I passionately believe that the success of our new alpha-emitting radiation therapy, Alpha DaRT, has the potential to create a paradigm shift in cancer care. Despite advances in conventional therapies, there are st...

January 27, 2020

Diffusing alpha-emitters radiation therapy (DaRT) uses interstitial radioactive seeds that continually release short-lived alpha-emitting atoms to treat cancer. Researchers in Israel have now published the positive results of a first-in-human clinical study evaluating...

Cancer is the second leading cause of death in the United States. Around the globe, cancer incidence has been steadily increasing over the past half-century. Read article in The Jerusalem Post here.

The question I have asked myself and many others most often over the pa...

December 1, 2019

Dear Colleagues and Friends,

Our fourth Alpha Tau Newsletter is full of fantastic updates that I am very excited to share with you.
 
I am thrilled to inform you that our first clinical trial results have been published! The exceptional results were presented in the I...

November 26, 2019

Alpha DaRT™ achieves a 78.6% complete response rate in management of challenging squamous cell carcinoma tumors.


Tel Aviv, Israel, November 26, 2019 – Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a...

October 7, 2019

October 7 is the birth date of Danish physicist Niels Bohr [1] (1885-1862). Bohr has a special significance for Alpha Tau, for two reasons. The first reason is because he was one of the key contributors to the foundational discoveries in atomic physics at the beginning...

October 2, 2019

"It is my honor to assume the duty of Chief Scientific Officer of ATM," said Prof. Keisari, "our alpha radiation-based brachytherapy has already demonstrated its potential to treat tumorous lesions in humans, and I see it as my mission to take this treat...

Please reload

Categories